Masimo Corporation announced that it is the recipient of one of Frost & Sullivan’s highest honors for Market Engineering: the 2000 Competitive Strategy Award. This award, based on independent research and analysis of companies in the health care industry, recognizes Masimo for its positive contribution to the blood gas monitoring equipment market.
According to Frost & Sullivan analyst, Minal Vasanawada, “Masimo has made a significant impact on the industry with its successful marketing of its proprietary Signal Extraction pulse oximetry technology, Masimo SET®. False alarms and erroneous readings due to patient and environmental factors have for long plagued pulse oximetry technology. By addressing this pressing need to have more accurate data from pulse oximeters in varied clinical settings including motion and low perfusion, Masimo has displayed a clear understanding of the primary competitive factors in this industry. Frost & Sullivan recognizes this outstanding achievement and awards Masimo with its Competitive Strategy Award.”
“Masimo is honored to be recognized by Frost & Sullivan for the advancement and contribution Masimo has made in the field of pulse oximetry,” said Joe E. Kiani, President and CEO of Masimo Corporation. “Our goal was to solve what other companies thought was unsolvable - to make pulse oximetry accurate during motion and low perfusion. We then set out to educate the industry and health care professionals with independent clinical studies by leading clinicians around the world and true side-by-side demonstrations. Today, over 25 clinical studies by independent researchers have proven Masimo Signal Extraction Technology to be the only pulse oximetry technology accurate under the most challenging conditions of motion and low perfusion and when it’s needed the most. We wish to thank the dedicated clinicians who, without any personal monetary reward, have spent their valuable time and resources to study Masimo SET®’s performance compared to conventional pulse oximetry and Masimo SET’s effect on improving patient care as well as reducing cost of care.”
Mr. Kiani continued, “By proving the breakthrough accuracy and reliability of Masimo SET® technology clearly and honestly, we have been able to attract over 30 leading patient monitoring companies, who make up over 50% of the world’s pulse oximeter suppliers - to adopt Masimo SET® as their standard pulse oximetry technology. These companies have spent significant resources to upgrade their products to Masimo SET® for the benefit of their customers; they should also be honored. Receiving honors such as this Frost & Sullivan Award and the appreciation from clinicians and patients who have been helped by our technology, renews our commitment to continue to advance signal processing and sensor technology for the benefit of patients and to be driven by a sense of fascination and accomplishment.”
Recently Masimo announced Radical, a product that is accelerating the standardization of Masimo SET® pulse oximetry throughout hospitals. The Radical Signal Extraction pulse oximeter allows clinicians to get access to Masimo SET®. It is three pulse oximeters in one: a standalone device for bedside monitoring, a detachable handheld pulse oximeter for ultra-portable monitoring and a monitor interface, called SatShare, which allows Radical to upgrade multi-parameter patient monitors to Masimo SET® technology. Radical can provide continuous and reliable arterial oxygen saturation monitoring anywhere throughout the continuum of care. With help from some of our partners, particularly Allegiance and Datex-Ohmeda, who have vast distribution resources and flexible acquisition programs, Masimo is making it easy for clinicians to get access to Radical to standardize their hospitals to Masimo SET® pulse oximetry.
